
    
      Up to 24 healthy subjects will be enrolled into 4 groups, with 6 subjects per group. Each
      subject will be randomised to receive a single oral dose of 10 mg or 20 mg HTL0016878
      solution and will have a single CSF sample taken via lumbar puncture at either 2 or 6 hours
      post-dose. Pharmacokinetic blood sampling and safety measures will continue until 24 hours
      post-dose.
    
  